Efficacy of paroxetine on longitudinal ADL and QOL in post-stroke depression

帕罗西汀对卒中后抑郁症纵向 ADL 和 QOL 的疗效

• 批准号: 20700455
• 负责人: TAKAHASHI Masanori
• 金额: $ 1.25万
• 依托单位: University of Occupational and Environmental Health, Japan
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20700455/
• 关键词: 脳卒中後うつ(PSD); 塩酸パロキセチン; ADL; QOL; 脳卒中後うつ

We administered paroxetine, one of the selective serotonin reuptake inhibitor (SSRI), or nicergoline as a control to patients with post-stroke depression (PSD) for eight weeks and evaluated the severity of depression, disabilities of stroke and QOL for eight months. The severity of depression was improved at the group which administered paroxetine during a medicine dosage period in comparison with the control group, but did not recognize a difference in ability of gait and ADL at the time of the medicine dosage end. However, it was the tendency that the hospitalization came to shorten in the group which administered paroxetine. The dosage of the SSRI for PSD did not affect longitudinal ADL and QOL. But it improves depression early to diagnose as PSD and administer SSRI, and it may shorten hospitalization.

我们给中风后抑郁症（PSD）患者服用帕罗西汀（选择性血清素再摄取抑制剂（SSRI）之一）或尼麦角林作为对照，为期八周，并评估抑郁症的严重程度、中风残疾和生活质量，为期八个月。与对照组相比，在服药期间施用帕罗西汀的组的抑郁严重程度得到改善，但在服药结束时未发现步态能力和ADL的差异。然而，服用帕罗西汀的组有住院时间缩短的趋势。治疗 PSD 的 SSRI 剂量不影响纵向 ADL 和 QOL。但早期诊断为 PSD 并服用 SSRI 可以改善抑郁症，并且可以缩短住院时间。